OPM tests first kinase inhibitor in clinic
Oncodesign Precision Medicine (OPM) has announced positive results of a Phase I trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV).
OPM-101 is intended for the treatment of resistant and metastatic cancers.
Philippe Genne, Chief Executive Officer of OPM, said: “We are pleased to demonstrate the safety of our candidate and the strong PK/PD correlation that exists. High target engagement is demonstrated at tolerated doses of OPM-101 throughout the treatment period. The modulation of TNFa production ex vivo can be considered as a key biomarker of target engagement for future clinical trials. The clinical results reported today not only highlight the consistency with the immunomodulatory effect of OPM-101 observed in preclinical studies, but also validate OPM-101 as a safe and effective inhibitor of the RIPK2 pathway.”
Proof-of-concept clinical trial
OPM is currently in the process of identifying the first clinical indication that the company will explore in a Phase Ib/IIa study before the end of 2024, to provide a first clinical proof of concept in a patient population capable of generating significant added value for the asset.
“These results validate OPM-101 as a highly specific, effective and well-tolerated inhibitor of the RIPK2 immune pathway,” added Jan Hoflack, Deputy CEO and Chief Scientific Officer of OPM. “The field related to this therapeutic approach is currently booming with new high quality preclinical and clinical scientific publications mentioning a potential role for an inhibitor like OPM-101 in multiple immuno-oncology indications, in addition to the already well-established rationale for the treatment of inflammatory bowel disease (IBD) and other inflammatory diseases.
“Our team is currently working to validate the different therapeutic options available for OPM-101, with the aim of launching a proof-of-concept clinical trial in relevant patients rapidly and efficiently before the end of the year. The current idea of a safe and effective RIPK2 inhibitor like OPM-101 suggests significant potential in both IBD and immuno-oncology, two of today’s largest pharmaceutical markets with significant unmet needs.”
Megan Thomas, Multimedia Editor, DDW
